Biotech Short Interest Dynamics
Recursion Pharmaceuticals (RXRX) has emerged as a focal point for short sellers within the biotech space, with 33.39% of its shares shorted as of October 5, 2026. The biotechnology sector is currently seeing heightened short-selling activity as investors balance long-term research potential against the immediate headwinds of rising capital costs.
Actionable Insight
The combination of a 33%+ short-to-float ratio and the inherent volatility of drug development stocks suggests that RXRX is a high-risk, high-reward play. Investors tracking this ticker should watch for shifts in borrow costs, which typically escalate as institutional sentiment turns decisively against such high-beta assets in the current macroeconomic climate.
Key Takeaways
- Short Interest: 33.39% of float.
- Sector: Biotechnology.
- Risk: High-beta volatility.
The Bottom Line
RXRX is heavily targeted by bears, making it a volatile ticker to watch for potential short-covering spikes in the biotech sector.
Signal data sourced from Seeking Alpha. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.